BioNexus Gene Lab announces 1-for-10 reverse stock split effective April 7, 2025 to regain Nasdaq compliance

BioNexus Gene Lab Corp

Reverse stock split at 1-for-10 ratio; effective 12:01 a.m. ET on April 7, 2025.
Company aims to cure Nasdaq bid price deficiency; must close above $1.00 for 10 consecutive days by May 1, 2025.
No fractional shares issued; shareholders receive cash in lieu based on April 4, 2025 closing price.
New CUSIP number 090628306; ticker symbol BGLC unchanged.
Shareholders holding electronically or in brokerage accounts adjusted automatically; physical certificate holders to receive instructions.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BioNexus Gene Lab Corp: Amended articles of incorporation to effect a 1-for-10 reverse stock split (effective 2025-04-07).

Change: charter amendment
Effective: 2025-04-07

Exact text from the filing

The Articles of Amendment regarding the reverse stock split was filed with the Wyoming Secretary of State on April 1, 2025

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-25-002406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.